Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

Original reporting
Published Oct 28, 2026, 5:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CHE
Neutral
medium confidence
Mentioned
$CHE
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CHENeutralMed
01

Why it matters

The earnings call provides fresh data on revenue growth and guidance, offering a modest trading edge.

02

Market read

Earnings data reinforces existing expectations, yielding limited but actionable insight for short‑term positioning.

03

What to watch

Potential cost pressures from central support functions may limit upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Chemed Corp (CHE) reported Q3 2026 results, noting a 12.2% YoY increase in VITAS revenue and reaffirming EPS guidance for 2026.

Company-level read

Ticker impact

$CHENeutralMedium confidence
Context

Management highlighted VITAS revenue up 12.2% YoY and reaffirmed 2026 EPS guidance at the high end.

Expected impact

modest upside as the market prices in steady guidance

Evidence & confidence

Guidance remains at the prior high end; no surprise elements, but the revenue beat supports a slight positive bias.

Market effects

Positive signal for the home health and hospice sector as VITAS shows strong growth.

Limited to U.S. healthcare investors.

Low

Counterpoint

If the market expected higher EPS growth, the guidance at the prior high end could be seen as a disappointment.

Key entities

  • Chemed Corp

    U.S. home health and hospice services provider.

  • VITAS Healthcare

    Chemed's primary hospice and home health subsidiary.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.